Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment

The multi-kinase inhibitor sorafenib is clinically approved for the treatment of patients with advanced hepatocellular carcinoma (HCC). We previously reported that fibroblast growth factor 3 and 4 (FGF3/FGF4) amplification is a predictor of a response to sorafenib. This study aims to analyze the relationship between FGF-FGF receptor (FGFR) genetic alterations and the response to sorafenib. Formalin-fixed, paraffin-embedded tissue specimens from HCC patients who had achieved a complete response (CR, N=6) or non-CR (N=39) to sorafenib were collected and were examined for FGF-FGFR gene alterations using next generation sequencing and copy number assay. FGFR mutations were detected in 5 of 45 (11.1%) cases. There was no significant association between FGFR mutation status and the response to sorafenib. We detected no increase in the FGF3/FGF4 copy number in CR cases. An FGF19 copy number gain was detected more frequently among CR cases (2/6, 33.3%) than among non-CR cases (2/39, 5.1%) (P = 0.024, Chi-squared test). In conclusion, a copy number gain for FGF19 may be a predictor of a response to sorafenib, in addition to FGF3/FGF4 amplification.

[1]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[2]  W. Sung,et al.  Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification , 2014, Hepatology.

[3]  Lincoln D. Stein,et al.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. , 2011, Cancer cell.

[4]  T. Bekaii-Saab,et al.  Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report , 2008, Journal of hematology & oncology.

[5]  M. Kudo,et al.  Complete Response of Advanced Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Sorafenib: A Case Report , 2011, Oncology.

[6]  B. Lemon,et al.  FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation , 2009, The Journal of Biological Chemistry.

[7]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[8]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[9]  A. Torre,et al.  Diagnosis and treatment of hepatocellular carcinoma: An update. , 2015, World journal of hepatology.

[10]  L. Gravitz.  Liver cancer , 2014, Nature.

[11]  A. Iafrate,et al.  Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[13]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[14]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[15]  Takahisa Kawaguchi,et al.  Large-Scale East-Asian eQTL Mapping Reveals Novel Candidate Genes for LD Mapping and the Genomic Landscape of Transcriptional Effects of Sequence Variants , 2014, PloS one.

[16]  S. Powers,et al.  Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. , 2013, Gastroenterology.

[17]  Ming-Chih Crouthamel,et al.  Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors , 2009, British Journal of Cancer.

[18]  M. Miyazaki,et al.  Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma , 2012, BMC Cancer.

[19]  David M. Thomas,et al.  FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. , 2012, Cancer discovery.

[20]  N. Izumi,et al.  Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[21]  Fabrice Andre,et al.  Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. , 2013, Cancer discovery.

[22]  Tohru Utsunomiya,et al.  FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma , 2013, Hepatology.

[23]  W. Koizumi,et al.  Rapid Regression of Advanced Hepatocellular Carcinoma Associated with Elevation of Des-Gamma-Carboxy Prothrombin after Short-Term Treatment with Sorafenib – A Report of Two Cases , 2010, Case Reports in Oncology.

[24]  J. Llovet,et al.  Liver cancer in 2013: Mutational landscape of HCC—the end of the beginning , 2014, Nature Reviews Clinical Oncology.